Asset Details
Do you wish to reserve the book?
Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia
Do you wish to request the book?
Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia
2010
Overview
Estrogen has important roles in the initiation and development of benign prostatic hyperplasia （BPH）. Regulators of the estrogen receptor （ER） are tissue- and cell-specific. We evaluated the effect of estrogen antagonist, raloxifene （Ral）, on the prevention and treatment of BPH by investigating its effect on the proliferation of two different prostate cell lines： a stromal cell line, WPMY-1, and a benign prostatic hyperplasia epithelial cell line, BPH-1. We additionally evaluated its effect on prostatic hyperplasia induced by estrogen and androgen in a rat model. The effect of Ral on the prevention of prostatic hyperplasia was analyzed by haematoxylin and eosin staining and quantitative immunohistochemistry （IHC） for proliferating cell nuclear antigen and α-smooth muscle actin. In vitro and in vivo, tamoxifen （Tam）, another anti-estrogen drug, and finasteride （Fin）, a drug for the clinical treatment of BPH, served as efficacy controls. The in vitro data showed that neither Ral nor Tam alone affected the proliferation of WPMY-1 and BPH-1, but both antagonized the effect of oestradiol in promoting the proliferation of the two cells. Results from the IHC staining of the rat prostates indicated that, similar to Tam and Fin, Ral inhibited the proliferation of stromal cells in vivo. Interestingly, in contrast to Tam, both Ral and Fin inhibited the proliferation of epithelial cells. Furthemore, Ral treatment much strongly decreased the number of prostatic acini and the surrounding layers of smooth muscle cells than Fin （P 〈 0.05）. Our data showed for the first time that Ral may have a role in the response of the rat prostate to selective ER modulators.
Publisher
Medknow Publications & Media Pvt. Ltd,Nature Publishing Group
Subject
5-alpha Reductase Inhibitors - therapeutic use
/ Aging
/ Animals
/ Cell Proliferation - drug effects
/ Estrogen Antagonists - pharmacology
/ Estrogen Antagonists - therapeutic use
/ Finasteride - therapeutic use
/ Humans
/ Male
/ Original
/ Proliferating Cell Nuclear Antigen - metabolism
/ Prostatic Hyperplasia - drug therapy
/ Prostatic Hyperplasia - prevention & control
/ Raloxifene Hydrochloride - pharmacology
/ Raloxifene Hydrochloride - therapeutic use
/ Rats
/ Selective Estrogen Receptor Modulators - pharmacology
/ Selective Estrogen Receptor Modulators - therapeutic use
/ 免疫组织化学染色
/ 受体拮抗剂
/ 增殖细胞核抗原
/ 细胞特异性
/ 良性前列腺增生
/ 雷洛昔芬
/ 预防效果
